I was just looking at the SMC website and their ST
Post# of 154563
(Total Views: 832)
Posted On: 08/27/2024 9:32:30 AM
I was just looking at the SMC website and their STAM mice line for MASH, noting that is also used to evaluate hepatocellular carcinoma (HCC). 100% of the mice develop HCC by 20 weeks. SMC laboratories can do CT evaluation for tumor burden and size to evaluate progression. I have no idea what labs etc Cytodyn contracted for but it is a 12 week study and frankly targeting progression to MASH and associated fibrosis,; the timeline is inconsistent with taking a poke at HCC. That said you need to realize that the pathophysiology resulting in MASH is on a continuum that can and does lead to HCC. HCC in humans has other causes, hepatitis B and C are sizable contributors but MASH is right up there. HCC is the third leading cause of cancer death.
I think Dr J wants somewhat expedited results in the murine MASH study under SMC which will trigger potential partnerships, while Cytodyn pursues their two priorities in oncology and inflammation. Smart chess move but I am not alone in realizing there is a lot of overlap with both oncology and inflammation when it comes to MASH.
“CytoDyn’s CEO, Dr. Jacob Lalezari, stated, “in addition to clarifying dosing and efficacy, the goal of this study is to eventually use the results to pursue partnerships in the MASH space. Although CytoDyn will be primarily focused on oncology and inflammation in the coming months, we do believe that leronlimab could have a significant role in the treatment of MASH, whether as a standalone therapeutic or in a combination therapy approach.”
Per SMC, nodules become present at 12 weeks, HCC present at 16 weeks, with 100% of mice expressing carcinogenesis at 20 weeks.
https://www.smccro-lab.com/Immuno-oncology/en/
I think Dr J wants somewhat expedited results in the murine MASH study under SMC which will trigger potential partnerships, while Cytodyn pursues their two priorities in oncology and inflammation. Smart chess move but I am not alone in realizing there is a lot of overlap with both oncology and inflammation when it comes to MASH.
“CytoDyn’s CEO, Dr. Jacob Lalezari, stated, “in addition to clarifying dosing and efficacy, the goal of this study is to eventually use the results to pursue partnerships in the MASH space. Although CytoDyn will be primarily focused on oncology and inflammation in the coming months, we do believe that leronlimab could have a significant role in the treatment of MASH, whether as a standalone therapeutic or in a combination therapy approach.”
Per SMC, nodules become present at 12 weeks, HCC present at 16 weeks, with 100% of mice expressing carcinogenesis at 20 weeks.
https://www.smccro-lab.com/Immuno-oncology/en/
(17)
(0)